K Ray Chaudhuri1, Anette Schrag2, Daniel Weintraub3,4, Alexandra Rizos1, Carmen Rodriguez-Blazquez5, Eugenia Mamikonyan3, Pablo Martinez-Martin5. 1. King's College London, Department of Neurosciences, Institute of Psychiatry, Psychology & Neuroscience and Parkinson Foundation Centre of Excellence, King's College Hospital, Denmark Hill, London, UK. 2. Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK. 3. Department of Psychiatry and Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. 4. Parkinson's Disease Research, Education and Clinical Center (PADRECC), Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA. 5. National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain.
Abstract
BACKGROUND: The Movement Disorder Society-sponsored Nonmotor Rating Scale is an update of the existing Parkinson's disease Nonmotor Symptoms Scale modified to address some limitations in Nonmotor Symptoms Scale scoring, structure, and symptom coverage. METHODS: PD patients were recruited from movement disorder centers in an international, multicenter study. The Movement Disorder Society Nonmotor Rating Scale, consisting of 13 domains plus a subscale for nonmotor fluctuations, was rater administered, along with the Nonmotor Symptoms Scale and other clinical assessments. Standard reliability and validity testing were conducted. RESULTS: Four hundred and two PD patients were recruited (mean age ± standard deviation, 67.42 ± 9.96 years; mean age at PD onset ± standard deviation, 59.27 ± 10.67 years; median Hoehn and Yahr stage 2 (interquartile range 2-3). Data quality was satisfactory for all Movement Disorder Society Nonmotor Rating Scale domains except sexual (6.7% missing data). There were no floor or ceiling effects for the Movement Disorder Society Nonmotor Rating Scale and nonmotor fluctuations total score; domains had no ceiling effects, but some floor effects (13.5%-83.5%). The Movement Disorder Society Nonmotor Rating Scale and nonmotor fluctuations total score internal consistency were acceptable (average Cronbach's alpha, 0.66 and 0.84, respectively); interrater reliability was excellent (intraclass correlation coefficient, >0.95); for test-retest reliability, the intraclass correlation coefficient was 0.84 for the Movement Disorder Society Nonmotor Rating Scale and 0.70 for Movement Disorder Society nonmotor fluctuations total score, and precision was excellent for the Movement Disorder Society Nonmotor Rating Scale (standard error of measurement, 25.30) and fair for nonmotor fluctuations (standard error of measurement, 7.06). Correlations between Movement Disorder Society Nonmotor Rating Scale score and the corresponding Nonmotor Symptoms Scale and Movement Disorder Society UPDRS scores were high. There were no significant sex or age effects. The Movement Disorder Society Nonmotor Rating Scale score increased with increasing PD duration, disease severity, and PD medication dose (all P < 0.001). CONCLUSIONS: The Movement Disorder Society Nonmotor Rating Scale is a valid measure for measuring the burden of a wide range of Nonmotor Rating Scale scores, including nonmotor fluctuations, in PD patients.
BACKGROUND: The Movement Disorder Society-sponsored Nonmotor Rating Scale is an update of the existing Parkinson's disease Nonmotor Symptoms Scale modified to address some limitations in Nonmotor Symptoms Scale scoring, structure, and symptom coverage. METHODS:PDpatients were recruited from movement disorder centers in an international, multicenter study. The Movement Disorder Society Nonmotor Rating Scale, consisting of 13 domains plus a subscale for nonmotor fluctuations, was rater administered, along with the Nonmotor Symptoms Scale and other clinical assessments. Standard reliability and validity testing were conducted. RESULTS: Four hundred and two PDpatients were recruited (mean age ± standard deviation, 67.42 ± 9.96 years; mean age at PD onset ± standard deviation, 59.27 ± 10.67 years; median Hoehn and Yahr stage 2 (interquartile range 2-3). Data quality was satisfactory for all Movement Disorder Society Nonmotor Rating Scale domains except sexual (6.7% missing data). There were no floor or ceiling effects for the Movement Disorder Society Nonmotor Rating Scale and nonmotor fluctuations total score; domains had no ceiling effects, but some floor effects (13.5%-83.5%). The Movement Disorder Society Nonmotor Rating Scale and nonmotor fluctuations total score internal consistency were acceptable (average Cronbach's alpha, 0.66 and 0.84, respectively); interrater reliability was excellent (intraclass correlation coefficient, >0.95); for test-retest reliability, the intraclass correlation coefficient was 0.84 for the Movement Disorder Society Nonmotor Rating Scale and 0.70 for Movement Disorder Society nonmotor fluctuations total score, and precision was excellent for the Movement Disorder Society Nonmotor Rating Scale (standard error of measurement, 25.30) and fair for nonmotor fluctuations (standard error of measurement, 7.06). Correlations between Movement Disorder Society Nonmotor Rating Scale score and the corresponding Nonmotor Symptoms Scale and Movement Disorder Society UPDRS scores were high. There were no significant sex or age effects. The Movement Disorder Society Nonmotor Rating Scale score increased with increasing PD duration, disease severity, and PD medication dose (all P < 0.001). CONCLUSIONS: The Movement Disorder Society Nonmotor Rating Scale is a valid measure for measuring the burden of a wide range of Nonmotor Rating Scale scores, including nonmotor fluctuations, in PDpatients.
Authors: David A Grimes; David Hubacher; Kavita Nanda; Kenneth F Schulz; David Moher; Douglas G Altman Journal: Lancet Date: 2005 Jul 9-15 Impact factor: 79.321
Authors: Caroline B Terwee; Sandra D M Bot; Michael R de Boer; Daniëlle A W M van der Windt; Dirk L Knol; Joost Dekker; Lex M Bouter; Henrica C W de Vet Journal: J Clin Epidemiol Date: 2006-08-24 Impact factor: 6.437
Authors: Haidar S Dafsari; Pablo Martinez-Martin; Alexandra Rizos; Maja Trost; Maria Gabriela Dos Santos Ghilardi; Prashanth Reddy; Anna Sauerbier; Jan Niklas Petry-Schmelzer; Milica Kramberger; Robbert W K Borgemeester; Michael T Barbe; Keyoumars Ashkan; Monty Silverdale; Julian Evans; Per Odin; Erich Talamoni Fonoff; Gereon R Fink; Tove Henriksen; Georg Ebersbach; Zvezdan Pirtošek; Veerle Visser-Vandewalle; Angelo Antonini; Lars Timmermann; K Ray Chaudhuri Journal: Mov Disord Date: 2019-02-04 Impact factor: 10.338
Authors: Leire Ambrosio; Mari Carmen Portillo; Carmen Rodriguez-Blazquez; Juan Carlos Martínez-Castrillo; Mayela Rodriguez-Violante; Marcos Serrano-Dueñas; Víctor Campos-Arillo; Nelida Susana Garretto; Tomoko Arakaki; Mario Álvarez; Ivonne Pedroso-Ibáñez; Ana Carvajal; Pablo Martinez-Martin Journal: Parkinsonism Relat Disord Date: 2016-02-15 Impact factor: 4.891
Authors: Claudia Trenkwalder; Bryan Kies; Monika Rudzinska; Jennifer Fine; Janos Nikl; Krystyna Honczarenko; Peter Dioszeghy; Dennis Hill; Tim Anderson; Vilho Myllyla; Jan Kassubek; Malcolm Steiger; Marco Zucconi; Eduardo Tolosa; Werner Poewe; Erwin Surmann; John Whitesides; Babak Boroojerdi; Kallol Ray Chaudhuri Journal: Mov Disord Date: 2010-11-18 Impact factor: 10.338
Authors: Dag Aarsland; Lucia Batzu; Glenda M Halliday; Gert J Geurtsen; Clive Ballard; K Ray Chaudhuri; Daniel Weintraub Journal: Nat Rev Dis Primers Date: 2021-07-01 Impact factor: 52.329
Authors: Carmen Rodriguez-Blazquez; Anette Schrag; Alexandra Rizos; K Ray Chaudhuri; Pablo Martinez-Martin; Daniel Weintraub Journal: Mov Disord Clin Pract Date: 2020-12-21
Authors: Jade E Kenna; Megan C Bakeberg; Anastazja M Gorecki; Alfred Chin Yen Tay; Samantha Winter; Frank L Mastaglia; Ryan S Anderton Journal: Mov Disord Clin Pract Date: 2021-01-05
Authors: D Santos García; T De Deus Fonticoba; J M Paz González; C Cores Bartolomé; L Valdés Aymerich; J G Muñoz Enríquez; E Suárez; S Jesús; M Aguilar; P Pastor; L L Planellas; M Cosgaya; J García Caldentey; N Caballol; I Legarda; J Hernández Vara; I Cabo; L López Manzanares; I González Aramburu; M A Ávila Rivera; M J Catalán; V Nogueira; V Puente; J M García Moreno; C Borrué; B Solano Vila; M Álvarez Sauco; L Vela; S Escalante; E Cubo; F Carrillo Padilla; J C Martínez Castrillo; P Sánchez Alonso; M G Alonso Losada; N López Ariztegui; I Gastón; J Kulisevsky; M Blázquez Estrada; M Seijo; J Rúiz Martínez; C Valero; M Kurtis; O de Fábregues; J González Ardura; C Ordás; L López Díaz; P Mir; P Martinez-Martin Journal: Parkinsons Dis Date: 2021-05-13